SANOFI U.S. SERVICES, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2017–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	6	2
2025	—	8	2
2024	—	8	2
2023	—	8	2
2022	—	8	2
2021	—	8	2
2020	—	8	2
2019	—	8	2
2018	—	8	2
2017	—	5	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
W STRATEGIES, LLC	—	38
MARSHALL & POPP, LLC	—	31
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)	—	6

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	72
SENATE	46
Centers For Medicare and Medicaid Services (CMS)	15
Health & Human Services, Dept of (HHS)	15
Natl Economic Council (NEC)	14
Food & Drug Administration (FDA)	7
Office of Management & Budget (OMB)	7
White House Office	7
Executive Office of the President (EOP)	3
Office of the Vice President of the United States	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	35
Pharmacy	Pharmacy	32
Copyright/Patent/Trademark	Copyright/Patent/Trademark	30
Health Issues	Health Issues	29
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	26
Trade (domestic/foreign)	Trade (domestic/foreign)	25
Budget/Appropriations	Budget/Appropriations	7

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1041

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

Show 21 more cited filings

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1041

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · first_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 7148119th Congress

Consolidated Appropriations Act, 2026

2026 · first_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R.7148

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · first_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · first_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1041

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

S. 1040119th Congress

Drug Competition Enhancement Act

2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1041

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

S. 1040119th Congress

Drug Competition Enhancement Act

2025 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1041

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · second_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 - One Big Beautiful Bill Act." Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: H.R.1

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · second_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 - One Big Beautiful Bill Act." Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: H.R.1492

HCONRES 14119th Congress

Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

2025 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to budget reconciliation, including H.Con.Res. 14.

Client expense: — · Firm income: $60,000

Matched citations: H.Con.Res. 14

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 1, FY25 budget reconciliation. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 1, FY25 budget reconciliation. Issues related to the 340B program.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

S. 1040119th Congress

Drug Competition Enhancement Act

2025 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · second_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $60,000

Matched citations: S.1041

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · first_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: H.R.1492

HCONRES 14119th Congress

Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

2025 · first_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Client expense: — · Firm income: $60,000

Matched citations: H.Con.Res. 14

Source: Senate LDA

SANOFI U.S. SERVICES, INC. — Lobbying Disclosure | Poliscope